Eczema drug afimkibart tested for Long-Term safety in new study

NCT ID NCT07223697

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 03, 2025 · Last updated Apr 30, 2026 · Updated 29 times

Summary

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema). It is for adults who already took part in earlier afimkibart studies. Researchers will track side effects and measure how well the drug controls eczema over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Best Skin Research LLC
RECRUITING

Camp Hill, Pennsylvania, 17011, United States
Centrum Medyczne Pratia Katowice I
RECRUITING

Katowice, Silesian Voivodeship, 40-081, Poland
Centrum Nowoczesnych Terapii "Dobry Lekarz"
RECRUITING

Krakow, 31-011, Poland
DermEdge
RECRUITING

Mississauga, Ontario, L4Y4C5, Canada
Klinika Ambroziak Dermatologia
RECRUITING

Warsaw, 02-953, Poland
Revival Research Institute, LLC
RECRUITING

Troy, Michigan, 48084, United States
Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie
RECRUITING

Rzeszów, 35-055, Poland

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS